275 related articles for article (PubMed ID: 33182650)
1. Novel FGFR4-Targeting Single-Domain Antibodies for Multiple Targeted Therapies against Rhabdomyosarcoma.
Alijaj N; Moutel S; Gouveia ZL; Gray M; Roveri M; Dzhumashev D; Weber F; Meier G; Luciani P; Rössler JK; Schäfer BW; Perez F; Bernasconi M
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33182650
[TBL] [Abstract][Full Text] [Related]
2. FGFR4-Targeted Chimeric Antigen Receptors Combined with Anti-Myeloid Polypharmacy Effectively Treat Orthotopic Rhabdomyosarcoma.
Sullivan PM; Kumar R; Li W; Hoglund V; Wang L; Zhang Y; Shi M; Beak D; Cheuk A; Jensen MC; Khan J; Dimitrov DS; Orentas RJ
Mol Cancer Ther; 2022 Oct; 21(10):1608-1621. PubMed ID: 35877472
[TBL] [Abstract][Full Text] [Related]
3. CD276-CAR T cells and Dual-CAR T cells targeting CD276/FGFR4 promote rhabdomyosarcoma clearance in orthotopic mouse models.
Timpanaro A; Piccand C; Dzhumashev D; Anton-Joseph S; Robbi A; Moser J; Rössler J; Bernasconi M
J Exp Clin Cancer Res; 2023 Nov; 42(1):293. PubMed ID: 37924157
[TBL] [Abstract][Full Text] [Related]
4. Preclinical development of a chimeric antigen receptor T cell therapy targeting FGFR4 in rhabdomyosarcoma.
Tian M; Wei JS; Shivaprasad N; Highfill SL; Gryder BE; Milewski D; Brown GT; Moses L; Song H; Wu JT; Azorsa P; Kumar J; Schneider D; Chou HC; Song YK; Rahmy A; Masih KE; Kim YY; Belyea B; Linardic CM; Dropulic B; Sullivan PM; Sorensen PH; Dimitrov DS; Maris JM; Mackall CL; Orentas RJ; Cheuk AT; Khan J
Cell Rep Med; 2023 Oct; 4(10):101212. PubMed ID: 37774704
[TBL] [Abstract][Full Text] [Related]
5. Preclinical Evaluation of the FGFR-Family Inhibitor Futibatinib for Pediatric Rhabdomyosarcoma.
Wu JT; Cheuk A; Isanogle K; Robinson C; Zhang X; Ceribelli M; Beck E; Shinn P; Klumpp-Thomas C; Wilson KM; McKnight C; Itkin Z; Sotome H; Hirai H; Calleja E; Wacheck V; Gouker B; Peer CJ; Corvalan N; Milewski D; Kim YY; Figg WD; Edmondson EF; Thomas CJ; Difilippantonio S; Wei JS; Khan J
Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627061
[TBL] [Abstract][Full Text] [Related]
6. RP215 single chain fragment variable and single domain recombinant antibodies induce cell cycle arrest at G0/G1 phase in breast cancer.
Yu F; Wang Y; Xiao Y; He Y; Luo C; Duan D; Li C; Xu S; Xiang T
Mol Immunol; 2014 May; 59(1):100-9. PubMed ID: 24534066
[TBL] [Abstract][Full Text] [Related]
7. Surfaceome Profiling of Cell Lines and Patient-Derived Xenografts Confirm FGFR4, NCAM1, CD276, and Highlight AGRL2, JAM3, and L1CAM as Surface Targets for Rhabdomyosarcoma.
Timpanaro A; Piccand C; Uldry AC; Bode PK; Dzhumashev D; Sala R; Heller M; Rössler J; Bernasconi M
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768928
[TBL] [Abstract][Full Text] [Related]
8. Development of nanobodies targeting hepatocellular carcinoma and application of nanobody-based CAR-T technology.
Lin K; Xia B; Wang X; He X; Zhou M; Lin Y; Qiao Y; Li R; Chen Q; Li Y; Feng J; Chen T; Chen C; Li X; Zhang H; Lu L; Liu B; Zhang X
J Transl Med; 2024 Apr; 22(1):349. PubMed ID: 38610029
[TBL] [Abstract][Full Text] [Related]
9. Preclinical Development of U3-1784, a Novel FGFR4 Antibody Against Cancer, and Avoidance of Its On-target Toxicity.
Bartz R; Fukuchi K; Ohtsuka T; Lange T; Gruner K; Watanabe I; Hayashi S; Oda Y; Kawaida R; Komori H; Kashimoto Y; Wirtz P; Mayer JA; Redondo-Müller M; Saito S; Takahashi M; Hanzawa H; Imai E; Martinez A; Hanai M; Häussinger D; Chapman RW; Agatsuma T; Bange J; Abraham R
Mol Cancer Ther; 2019 Oct; 18(10):1832-1843. PubMed ID: 31350344
[TBL] [Abstract][Full Text] [Related]
10. Fibroblast growth factor receptor 4 (FGFR4) and fibroblast growth factor 19 (FGF19) autocrine enhance breast cancer cells survival.
Tiong KH; Tan BS; Choo HL; Chung FF; Hii LW; Tan SH; Khor NT; Wong SF; See SJ; Tan YF; Rosli R; Cheong SK; Leong CO
Oncotarget; 2016 Sep; 7(36):57633-57650. PubMed ID: 27192118
[TBL] [Abstract][Full Text] [Related]
11. Selection of human single domain antibodies (sdAb) against thymidine kinase 1 and their incorporation into sdAb-Fc antibody constructs for potential use in cancer therapy.
Velazquez EJ; Cress JD; Humpherys TB; Mortimer TO; Bellini DM; Skidmore JR; Smith KR; Robison RA; Weber SK; O'Neill KL
PLoS One; 2022; 17(3):e0264822. PubMed ID: 35239730
[TBL] [Abstract][Full Text] [Related]
12. Strategies to inhibit FGFR4 V550L-driven rhabdomyosarcoma.
Fiorito E; Szybowska P; Haugsten EM; Kostas M; Øy GF; Wiedlocha A; Singh S; Nakken S; Mælandsmo GM; Fletcher JA; Meza-Zepeda LA; Wesche J
Br J Cancer; 2022 Nov; 127(11):1939-1953. PubMed ID: 36097178
[TBL] [Abstract][Full Text] [Related]
13. Fibroblast growth factor 19 is correlated with an unfavorable prognosis and promotes progression by activating fibroblast growth factor receptor 4 in advanced-stage serous ovarian cancer.
Hu L; Cong L
Oncol Rep; 2015 Nov; 34(5):2683-91. PubMed ID: 26323668
[TBL] [Abstract][Full Text] [Related]
14. FGFR4 signaling couples to Bim and not Bmf to discriminate subsets of alveolar rhabdomyosarcoma cells.
Wachtel M; Rakic J; Okoniewski M; Bode P; Niggli F; Schäfer BW
Int J Cancer; 2014 Oct; 135(7):1543-52. PubMed ID: 24550147
[TBL] [Abstract][Full Text] [Related]
15. Joining the in vitro immunization of alpaca lymphocytes and phage display: rapid and cost effective pipeline for sdAb synthesis.
Comor L; Dolinska S; Bhide K; Pulzova L; Jiménez-Munguía I; Bencurova E; Flachbartova Z; Potocnakova L; Kanova E; Bhide M
Microb Cell Fact; 2017 Jan; 16(1):13. PubMed ID: 28114943
[TBL] [Abstract][Full Text] [Related]
16. Rapid liposomal formulation for nucleolin targeting to rhabdomyosarcoma cells.
Dzhumashev D; Anton-Joseph S; Morel VJ; Timpanaro A; Bordon G; Piccand C; Aleandri S; Luciani P; Rössler J; Bernasconi M
Eur J Pharm Biopharm; 2024 Jan; 194():49-61. PubMed ID: 38029941
[TBL] [Abstract][Full Text] [Related]
17. Fibroblast Growth Factor 15/19 in Hepatocarcinogenesis.
Alvarez-Sola G; Uriarte I; Latasa MU; Urtasun R; Bárcena-Varela M; Elizalde M; Jiménez M; Rodriguez-Ortigosa CM; Corrales FJ; Fernández-Barrena MG; Berasain C; Avila MA
Dig Dis; 2017; 35(3):158-165. PubMed ID: 28249259
[TBL] [Abstract][Full Text] [Related]
18. In vitro effects and ex vivo binding of an EGFR-specific immunotoxin on rhabdomyosarcoma cells.
Niesen J; Brehm H; Stein C; Berges N; Pardo A; Fischer R; Ten Haaf A; Gattenlöhner S; Tur MK; Barth S
J Cancer Res Clin Oncol; 2015 Jun; 141(6):1049-61. PubMed ID: 25433506
[TBL] [Abstract][Full Text] [Related]
19. Highly Specific Blood-Brain Barrier Transmigrating Single-Domain Antibodies Selected by an In Vivo Phage Display Screening.
Aguiar SI; Dias JNR; André AS; Silva ML; Martins D; Carrapiço B; Castanho M; Carriço J; Cavaco M; Gaspar MM; Nobre RJ; Pereira de Almeida L; Oliveira S; Gano L; Correia JDG; Barbas C; Gonçalves J; Neves V; Aires-da-Silva F
Pharmaceutics; 2021 Oct; 13(10):. PubMed ID: 34683891
[TBL] [Abstract][Full Text] [Related]
20. Interrupting the FGF19-FGFR4 Axis to Therapeutically Disrupt Cancer Progression.
Lang L; Shull AY; Teng Y
Curr Cancer Drug Targets; 2019; 19(1):17-25. PubMed ID: 29557750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]